A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer.

When the refined model was applied to the KRAS-WT CRC data, the resulting difference in PFS between the predicted-sensitive and predicted-resistant group was highly significant (median 147 days vs. 56.5 days in the predicted sensitive and resistant groups, respectively, p < 0.0001) (Figure 3B and 3C ).

also in 132,142 other papers